Cargando…
Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Autores principales: | Shimokihara, Kota, Kawahara, Takashi, Suzuki, Taisei, Mochizuki, Taku, Takamoto, Daiji, Teranishi, Jun‐ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Yao, Masahiro, Uemura, Hiroji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799614/ https://www.ncbi.nlm.nih.gov/pubmed/29445483 http://dx.doi.org/10.1002/ccr3.1328 |
Ejemplares similares
-
Foreign body in the bladder: A case report
por: Shimokihara, Kota, et al.
Publicado: (2017) -
Xanthogranulomatous Pyelonephritis with Incomplete Double Ureter
por: Hayashi, Yutaro, et al.
Publicado: (2017) -
Port site recurrence after laparoscopic radical nephrectomy: a case report
por: Shimokihara, Kota, et al.
Publicado: (2017) -
Ductal Adenocarcinoma of the Prostate: A Case Report
por: Hayashi, Yutaro, et al.
Publicado: (2016) -
The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis
por: Mochizuki, Taku, et al.
Publicado: (2017)